Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
May 16, 2022 06:30 ET
|
Chimerix, Inc.
– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics – – Transaction Allows for Focus on Development Pipeline – –...
Chimerix to Participate in Maxim Group Panel Discussion
May 12, 2022 16:15 ET
|
Chimerix, Inc.
DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022
May 09, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Present at Maxim Group 2022 Virtual Growth Conference
March 21, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update
March 01, 2022 07:00 ET
|
Chimerix, Inc.
– TEMBEXA RFP Response Submitted and Under Review with BARDA – – Pre-Clinical CMX521 Data Accepted for Late Breaking Oral Presentation at International Conference on Antiviral Research – – ONC201...
Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference
February 28, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
February 24, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel...
Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022
February 22, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at B. Riley Virtual Oncology Conference
January 20, 2022 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
January 18, 2022 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...